Browse All

Current Filters

CLEAR FILTER x

TITLE

The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD

Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis

Estimating the 10-Year Time-savings Benefits of Lecanemab Treatment

Real-world Delays in Anti-amyloid Therapy Initiation Following Diagnosis of Early-stage Alzheimer’s Disease